Approaches for the systematic review and evaluation of chemical toxicity are currently being reconsidered, with a specific focus on the evaluation of individual studies and their integration into the overall body of evidence. This renewed interest has arisen, in part, as a result of several prominent reviews of these approaches by special committees of the National Research Council (NRC), among others. We conducted a critical evaluation of several available frameworks for evaluating study quality. We assessed the criteria separately for human, animal, and in vitro studies as well as for systematic reviews. We then evaluated commonalities across disciplines. We also considered the potential implications of applying criteria frameworks and how they bear on fundamental risk assessment questions. We found that the available frameworks within each discipline differed in terms of their intended purpose and level of guidance for decision making. All the frameworks across disciplines shared common themes, however, including the adequate reporting of specific details of study conditions and design/protocol, selection and randomization of study groups (where applicable), outcome assessment methods and applicability (e.g., validity and reliability), avoidance of selective reporting, and the consideration of potential confounders or bias. We identified the most informative study quality considerations, which will enable researchers to implement more objective and standardized methods for evaluating studies and, ultimately, improve risk assessment methods.
1. Introduction
Study quality and risk of bias
Approaches to the systematic review and evaluation of the toxicity of chemicals are currently being reconsidered. This has arisen, in part, as a result of several prominent reviews by, among others, special committees of the National Research Council (NRC). The United States Environmental Protection Agency (US EPA) has undertaken a process to reform its methods for assessments under its Integrated Risk Information System (IRIS) and seeks input and advice from stakeholders. A key element of these process reforms e one that can be applied routinely and similarly across the studies under consideration as well as across assessments e is the identified need for objective and standardized methods for evaluating the "quality" of individual studies. The aim is to provide a consistent and objective system for bringing study strengths and shortcomings to bear on their evaluation as evidence of potential toxic
effects.
Exactly what is meant by a study's "quality" has not been defined precisely, or, at least, it has not been defined in exactly the same way in different discussions of the issue. But the general sense is that a review should include an assessment of the study design's soundness for its immediate intended purposes; the adequacy of precautions taken to avoid potential impacts on the results from unintended or uncontrolled causes (that is, influences aside from the one being tested); the care taken to execute the protocol correctly; and the adequacy and completeness of the analysis as well as documentation of the conduct and the results. All of these factors ultimately bear on whether the results of the evaluated study should be regarded as reliable and unambiguous for the interpretation of causal associations between the substance and the outcome of interest.
The term "risk of bias" has been applied to some, but not all, of the evaluation criteria for data quality. Because it is a new term, it appears that different discussants are assigning it varying meanings, and it is important to understand the intended implications in those discussants' particular uses of the term. The use of the word "bias" implies that the concern is for sources of possible systematic or directional error, as opposed to mere imprecision that results from statistical fluctuation (for example, because of small numbers of animals investigated or because of difficulty maintaining air concentration precisely at its target level). The use of the term "risk" implies that the issue is the potential for directional bias, as opposed to the determination that the biasing factor has indeed affected the results. That is, what is assessed is the sufficiency of steps to eliminate or control the influence of the biasing factor, rather than an assessment of the degree to which particular experimental results might have, in fact, been skewed.
The NRC (2014) review of the IRIS process makes the distinction as follows:
The committee notes that assessing the quality of the study is not equivalent to assessing the risk of bias in the study. An assessment of study quality evaluates the extent to which the researchers conducted their research to the highest possible standards and how a study is reported. Risk of bias is related to the internal validity of a study and reflects study-design characteristics that can introduce a systematic error (or deviation from the true effect) that might affect the magnitude and even the direction of the apparent effect. [emphasis added] In their guidance on systematic review (which includes details on conducting study quality assessments), the National Toxicology Program's (NTP) Office of Health Assessment and Translation (OHAT) echoed the distinction between imprecision and systematic error but went somewhat farther, by suggesting that the systematic error potential noted in risk of bias is not just related to, but is, in fact, equivalent to the evaluation of a study's internal validity (NTP, 2015a) . Note, however, that OHAT's preliminary guidance, issued in 2013, was less clear about the distinction between study quality and "risk of bias," seemingly using the terms interchangeably (NTP, 2013a) . Only in the first applications of their risk of bias approach (e.g., the assessment of bisphenol A; NTP, 2013b) did OHAT begin to specifically refer to "risk of bias" as a term that is synonymous with internal validity.
The concepts of risk of bias and study quality are nonetheless related. Procedures to ensure quality, such as the use of standardized methods, quality control procedures, and transparent reporting, are put in place to minimize the possibility of introducing sources of bias. Standard protocols (such as Organisation for Economic Co-operation and Development [OECD] guidelines for specific test types) are developed primarily to mandate steps to avoid known pitfalls and to avoid inadvertent introduction of unknown extraneous factors into an untested aspect of study design. Even unbiased random error is unbiased only in the long run, over multiple iterations of an experiment or study. In any one experiment, however, the random fluctuations can, by chance, be skewed away from the true mean values. If quality and bias measures are to be applied to individual studies, as many of these criteria systems intend, there is not a very clear distinction between study-specific random skewing and more systematic skewing potential. If the possibility of systematic skewing is at issue, the question still remains whether the factor actually affected the results of an individual study and, if so, how much and in what direction. Frequently, the direction and magnitude of skewing may be unknown. Moreover, it would seem that if one examines two studies with identical risk-of-bias profiles, except that one has a markedly larger number of animals or number of distinct dose groups, then this measure of quality (and not of bias) would affect the perceived dependability of the measured results as an index of the true causative relationship being investigated e that is, it would affect internal validity.
Another caveat about the use of the term "risk of bias" is that there are some aspects of bias that operate at the level of collections of studies e most notably, publication bias. For a study for which all the potential extraneous factors have been controlled, most of the evaluation systems will concur about its internal validity. But the choice of what studies to publish, what results of those studies to feature and document in the publications, which among several alternative analysis processes to pursue, whether those manuscripts are accepted for publication, and even what studies to undertake in the first place all can affect and bias the array of outcomes available in the literature, even if each individual study result that is reported is objective and reliable. Care must be taken in projecting the evaluations of quality or bias for individual studies into a characterization of the overall reliability of the body of studies collectively.
Methods
We conducted an evaluation of several of the available study quality criteria systems (Table 1) , pulling out and systematically comparing the specific criteria that the systems require evaluators to examine for each rated study. The intent is that this analysis will help further the general discussion about available study quality evaluation systems and the features that should be adopted in any system that might be established as part of the larger risk assessment methods improvement effort. Because the types of studies considered (i.e., animal, in vitro, human, and systematic reviews) have different designs e and, thus, different considerations for quality e we have evaluated these types of evidence separately and have summarized them in four separate tables (Tables 3e6). We assessed the following systems for evaluating the quality of studies or systematic reviews: the Klimisch system (Klimisch et al., 1997) ; OECD Guidance Document (GD) 34 (OECD, 2005) ; the Toxicological Data Reliability Assessment Tool (ToxRTool) (European Commission, Undated); the approaches that have been used in recent IRIS systematic review documents (US EPA, 2013), notably the recent risk-of-bias evaluations for inorganic arsenic (US EPA, 2014a) 1 ; the framework being developed by NTP's OHAT (NTP, 2013a (NTP, , 2015a , as applied to the risk-of-bias assessment of perfluorinated compounds (NTP, 2013b,c); Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for animal research (Kilkenny et al., 2010) ; the Navigation Guide for systematic reviews (Koustas et al., 2013 Woodruff and Sutton, 2014; Johnson et al., 2014; Lam et al., 2014) , the "assessment of multiple systematic reviews" (AMSTAR) system (Shea et al., 2007) ; the "strengthening the reporting of observational studies in epidemiology" (STROBE) system (von Elm et al., 2007a,b,c,d,e) ; and the Systematic Approach for Scoring Human Data, as developed by Money et al. (2013) . The types of studies (i.e., human, animal, in vitro, systematic reviews) addressed in each system are summarized in Table 1 . The specific criteria for each system are summarized in four tables, one each for: human studies (Table 3) , animal studies (Table 4) , in vitro studies (Table 5) , and systematic reviews (Table 6 ). Several of the criteria systems cover more than one of the study types. Although these 10 particular criteria systems do not exhaust the list of those that have been put forth, they provide a good overview of the main systems aimed at broad usage. Overall, the criteria systems differ in their purpose and specific recommendations e some only provide suggestions for information that should be reported by study authors, others suggest specific criteria that should be fulfilled by study authors, and others provide rating scales for use to assess the relative level of quality for a study based on the scores it receives. The entries used in the tables correspond to each of these types of recommendations/guidelines.
Findings
Although all of the reviewed systems are currently being applied for similar purposes for use in hazard and risk assessment, each differs in terms of its initial objectives and evolution. As discussed further below, ARRIVE and STROBE were developed as publication criteria (i.e., their purpose is to define reporting requirements); Klimisch and ToxRTool incorporate reporting criteria as well as study design and conduct criteria; OECD GD 34 is a study validation system; the IRIS document approaches, the OHAT framework, and the Navigation Guide specifically address risk of bias (internal validity); and the AMSTAR system includes reporting requirements as well as a checklist for assessing specific aspects of methodological quality in systematic reviews.
Broadly speaking, these criteria systems fit into one of three historical strains: (1) guidelines for study design and conduct according to standardized protocols (e.g., OECD Guidelines Studies), (2) standards for thorough recordkeeping and reporting of study conduct and results (e.g., Good Laboratory Practice [GLP] standards), and (3) methods for evaluating the quality of existing studies along a number of criteria and assessing or rating the overall reliability of a study (e.g., Klimisch ratings). Clearly, these three strains are related, because they refer to an overarching set of standards of good practice and the avoidance of widely recognized pitfalls. Guidelines for design and conduct require that new studies follow practices that aim to avoid issues that can compromise the reliability and informativeness of results; reporting standards aim to ensure that new studies document adherence to good practices Dates of study initiation and completion Objectives and procedures/methods (including all stated above) and any deviations from protocol Names of all personnel involved in the study Data calculations and statistical analyses Findings of quality assurance inspections Storage location of all specimens, raw data, and final report Archiving Retain raw data, records, protocols, specimens, correspondence, and final report and do not hide potential shortcomings from those using the studies in assessments; and quality rating systems aim retrospectively to score adherence to such principles and codify judgments about how well they have been met and, hence, how reliable the studies should be deemed to be.
Indeed, as we discuss further below, some retrospective quality Guideline Key: Discuss ¼ Address this issue in some way (no specific criteria and not considered directly as part of the scored 15 questions in the IRIS RoB framework); Report ¼ Reporting requirement; Score ¼ Scored for category based on the extent that issues were addressed; Y/N ¼ Criteria fulfilled (i.e., "Yes" or "No"). Sources: IRIS RoB ¼ US EPA (2013, 2014a) . Koustas et al. (2013 Koustas et al. ( , 2014 ; Woodruff and Sutton (2014) ; Johnson et al. (2014) ; Lam et al. (2014) . * Indicates a criteria (or system) that is specifically stated as a risk-of-bias consideration. All the criteria in the IRIS, OHAT, and Navigation Guide approaches are considered risk of bias issues. The only exception is the "Generalizability" criteria for IRIS, which is discussed in the context of study quality in US EPA's original guidance document (US EPA, 2013).
(a) The quality criteria below are specific to Money et al. (2013) ; the authors also state that all methodology and results should be "comprehensively and transparently" reported according to guidelines such as the STROBE guidelines. If all the criteria detailed in this table are fulfilled, overall, the study is considered "reliable without restriction." Money et al. (2013) also provide guidelines for overall ranking of a study if some criteria are missed, which correspond with overall ratings of "reliable with restrictions," "not reliable," or "not assignable." (b) The Navigation Guide was originally developed for systematic reviews of animal studies, but it has also been applied for epidemiology studies in a systematic review of perfluorinated compounds .
(c) The authors stipulate that this information should be provided separately for cases and controls in caseecontrol studies or exposed and unexposed groups in cohort/crosssectional studies. evaluation systems were expressly designed to monitor the degree of adherence to the specific design and documentation standards. Current interest in developing a standardized and widely applicable system for examining and evaluating study quality refer back to precedents in all three of the historical strains named above. Our discussion of these systems below tries to respect the different original purposes but nonetheless examine the various precedents for insight into useful and necessary properties of a new study quality evaluation system.
Human study quality criteria systems
Some of the systems that are relevant to epidemiological and other human studies (IRIS, OHAT, STROBE, the Navigation Guide, and Money et al., 2013) are quite similar, while others vary considerably in their recommendations for addressing study quality. The STROBE guidelines (von Elm et al., 2007a,b,c,d,e) are limited to reporting requirements, i.e., the criteria are lists of methods and issues that all studies should report (e.g., study size (c) Criteria marked "Report" for ToxRTool must be fulfilled in order to achieve a "reliable" score.
(d) Study characteristics that should be reported are not explicitly stated but are provided in example tables for animal studies in the arsenic and perfluorinated compounds assessments, for IRIS and OHAT, respectively. (e) The Navigation Guide system has specific reporting requirements for reproductive and developmental study methodologies.
and data sources). However, the STROBE guidelines do not make any recommendations regarding which methods are preferred, for quality reasons, or how any of the listed criteria may affect study results. In contrast, the other three systems require the evaluation of the appropriateness of the chosen design and methods. The Money et al. (2013) study developed a tiered study quality system based on the Klimisch system for animal and in vitro studies (Klimisch et al., 1997 ; see Section 2.2). Under this system, if a study fulfills a certain set of criteria, it can be considered "reliable without limitations." The remaining three tiers outline how to evaluate studies missing some of these criteria as either "reliable with restrictions," "not reliable," or "not assignable" (i.e., do not contain sufficient detail regarding methodology to assess quality or are only available as short abstracts or summaries in secondary literature). Although bias is considered within the criteria, Money et al. (2013) define study quality more broadly than issues of bias.
The OHAT risk-of-bias criteria, which include "15 questions" for addressing risk of bias, go a step further than the system developed by Money et al. (2013) . The assessor is told to assign a rating of "þþ," "þ," "À," or "À À" for each question based on the degree to which the study addresses it, corresponding to "definitely low," "probably low," "probably high," or "definitely high" risk of bias. The questions vary slightly among study types (cohort, crosssectional, and case series), depending on applicability. The official NTP OHAT handbook and supplemental materials published in 2015 provide explicit instructions and examples regarding how to assign a risk-of-bias rating for each question (NTP, 2015a,b) . For example, for the question, "Did selection of study participants result in appropriate comparison groups?," NTP states that, for cohort and cross-sectional studies, "definitely low risk of bias" means that there is direct evidence that the exposed and unexposed subjects were similar (e.g., recruited from the same eligible population via the same method of ascertainment, recruited within the same time frame, and had similar participation/response rates) (NTP, 2013a (NTP, , 2015b .
Additional explanation of how to specifically apply the risk-ofbias process methods can also be found in the NTP perfluorinated compounds systematic review document (NTP, 2013c) and the draft risk-of-bias assessment for bisphenol A and obesity (NTP, 2013b) . Note that OHAT guidance now specifically distinguishes between risk of bias and methodological quality (NTP, 2015a), but, in preliminary OHAT guidance, the two concepts appeared to be interchangeable (NTP, 2013a). The OHAT guidance on how to determine overall tiers of quality for each study is clear. The system guides the reader through the requirements for a study to be considered "Tier 1," "Tier 2," or "Tier 3," based on overall risk of bias.
The IRIS risk-of-bias criteria were adapted from the OHAT system, but appear to have been slightly modified. The IRIS criteria are detailed and explicit, assigning a score for each criterion based on the degree to which the study addresses it. At this time, the most detailed instructions regarding the IRIS criteria are provided in the Draft Development Materials for Arsenic (US EPA, 2014a), because (c) Criteria marked "Report" for ToxRTool must be fulfilled in order to achieve a "reliable" score.
an official guidance document has not been published. The provided recommended ratings ("þþ," "þ," "À," or "À À") are based on the likelihood of bias (definitely low, probably low, probably high, or definitely high risk of bias). The Draft Development Materials for Arsenic (US EPA, 2014a) provide a table to use for determining the overall quality tier for each study (i.e., "high" or "low" overall risk of bias). The overall tier is determined based on how many of the individual 15 questions were rated as a "À À" or "À." The table lacks clarity, especially in comparison to OHAT's guidance on overall quality tiers, and may be difficult for some readers to use as intended. Finally, it should be noted that, in addition to the 15 questions provided in the arsenic draft development materials, the general guidelines US EPA put forth for IRIS assessments based on the 2011 NRC recommendations (US EPA, 2013) provide additional qualitative guidance for evaluating study quality and general considerations that should be used to make quality judgments. In this document, however, the authors never use the phrase "risk of bias" when discussing study quality, and it appears that, based on further recommendations made by NRC in 2014 (NRC, 2014), IRIS shifted its focus from general study quality to specifically addressing risk of bias (as seen in the arsenic assessment). Note that although NRC recommended rigorously evaluating study quality, the NRC review does not specifically suggest an assessment of "risk of bias" (NRC, 2011). The Navigation Guide system (Koustas et al., 2013 Woodruff and Sutton, 2014; Johnson et al., 2014; Lam et al., 2014) , although targeted specifically at systematic reviews of animal studies, has also been applied to human data. This system shares many of the same criteria as the OHAT system, and the authors state that their risk of bias assessment was also adapted from the Agency for Healthcare Research and Quality (AHRQ, 2012) and a series of papers by Guyatt et al. (2011a,b,c,d ,e,f,g,h,i) and Balshem   Table 6 Criteria for the quality evaluation of systematic reviews. Lam et al. (2014) . * Indicates a criteria (or system) that is specifically stated as a risk of bias consideration. (a) Reviewers should err on the side of inclusion (i.e., it is better to include a study in the systematic evaluation and examine the impact of potential limitations, rather than exclude a study and lose any information it could have provided). (b) IRIS criteria require that very specific details be provided (e.g., description of comparison groups and prevalence of important confounders in these groups as well as the preference that reviewers present study sizes by exposure/outcome group). (c) OHAT's risk of bias system is the same as IRIS but with fewer details provided in the guidance. OHAT states these criteria are based on the Guyatt et al. (2011b) "GRADE" guidelines for risk of bias. (d) No specific requirements for quality criteria; AMSTAR simply states that the criteria should be developed a priori and described. (e) For pooled results, a test should be done to ensure that studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity). If heterogeneity exists, a random effects model should be used and/or the clinical appropriateness of combining these results should be considered. (f) The quality of the individual studies are qualitatively evaluated and pooled to form overall conclusions on the body of evidence depending on the likelihood that bias and confounding indicate possible alternative explanations for associations. Categories are "sufficient," "suggestive," or "inadequate" epidemiologic evidence of an association consistent with causation, or "epidemiologic evidence consistent with no association." (g) Based on the evidence, categorize as "known," "presumed," or "suspected" hazard to humans or "not classifiable or not identified to be a hazard to humans." (h) Based on the evidence, categorize a particular exposure as "known to be toxic," "probably toxic," "possibly toxic," "not classifiable," or "probably not toxic" (in this framework, this is applied specifically to reproductive and developmental health). et al. (2011) . The Navigation Guide provides a system to determine whether there is a "low risk of bias," a "probably low risk of bias," or a "high risk of bias" (or "not applicable," when appropriate) for a series of risk-of-bias criteria. Unlike the OHAT system, however, in the Navigation Guide system there are fewer criteria to score risk of bias. The Navigation Guide includes a set of eight questions addressing the issues of consistent recruitment of participants, exposure group concealment (personnel and outcome assessors), exposure measurement methods, methods to reduce confounding, outcome reporting, and financial conflict of interest. This last criterion distinguishes the Navigation Guide from IRIS and OHAT. Although IRIS and OHAT state that the funding source of a study should be reported, the Navigation Guide scores each study for risk of bias based on funding source.
Only two of the available systems that were reviewed (IRIS and OHAT) provide any guidance on rating the quality of controlled human exposure studies, which incorporate some concepts that are relevant to animal studies (e.g., storage of samples, randomization, blinding) and also some that are specific to human subjects (e.g., participant inclusion/exclusion criteria). These studies, as well as other studies that may be outside of traditional definitions (e.g., biomonitoring studies), may require a rating approach that combines considerations from different study types. Good Clinical Practice (GCP) guidelines may also be useful for evaluating the quality of these types of studies (ICH, 1996) .
Despite differences in their intended application, there are some similarities among the five human study criteria systems reviewed. At least four of the five systems clearly note that reporting, if not scoring, is needed for the following issues: blinding (for outcome assessors and for personnel and participants in controlled human exposure studies), participation rate/attrition, the validity of the comparison groups, statistical methods, data measurement methods, sources of bias/confounding and how they were reduced, exposure characterization, appropriate outcome assessment methods, and the presentation of both adjusted and unadjusted results of analyses. All five systems also require that authors report funding source/conflict of interest; however, only the Navigation Guide scores studies based on funding source. Only two out of the five systems mention the importance of evaluating the generalizability of results, reporting the study limitations, and considering the interpretation of the results. Regarding interpretation, in particular, only the Money et al. (2013) guidelines state that a reliable study should allow for "unambiguous interpretation;" in other words, the methods and results are sufficient so that the reader can draw causal inferences with respect to exposure and outcome without appreciable limitations or uncertainty. Finally, only the IRIS system mentions evaluating study power via statistical analysis, and only the STROBE guidance (von Elm et al., 2007a,b,c,d,e) and Navigation Guide note that authors should always report the objectives of the study.
Animal and in vitro study quality criteria review systems
Like the human study criteria systems, the systems aimed at assessing animal experiments e ARRIVE, Klimisch, OECD GD 34, ToxRTool, IRIS, and OHAT e vary in their recommendations and the purpose of their criteria. Several of these systems, however, are interrelated and based around the same underlying principals. For example, the Klimisch system is based heavily on the principals of GLP and OECD test guidelines. The ToxRTool is a refinement of the general criteria described by Klimisch. GLP principles merit a brief discussion. GLP is a quality management system for non-clinical studies that provides a framework for how laboratory studies are planned, performed, monitored, recorded, reported, and archived. There are several regulatory agencies with GLP regulations or guidelines (US EPA, United States Food and Drug Administration [US FDA], and OECD), each of which vary slightly. In general, however, to be considered a GLP study, a researcher must follow a detailed set of criteria that include specific requirements for personnel, facilities, equipment, procedures, animal care, test materials, study protocol, data recording, and reporting (see Table 2 ). Perhaps most importantly, GLP requires retention of all raw data and the preparation of a complete, independently audited study report, including objectives, design, methods, and all results and supporting data. Studies conducted under GLP are generally considered robust and of sufficient quality for inclusion in causal analyses, because many of the precepts of GLP requirements (and of defined protocols such as OECD test guidelines) are aimed at ensuring that quality considerations are addressed in the study design and conduct. This said, it is nonetheless the case that the quality evaluation of GLP studies is a function of their merits under the same set of evaluation criteria that apply to the evaluation of other, non-GLP studies. Conducting studies with established test guidelines and in compliance with GLP regulations are requirements for acceptance by many regulatory authorities.
As noted above, GLP standards have heavily influenced several of the quality criteria systems. The Klimisch system, while incorporating GLP and OECD guidelines, does not provide detailed guidance on specific quality factors when used alone. ToxRTool (European Commission, Undated) is a newer system that was developed using Klimisch principles, but with the intention to add more explicit criteria for assigning an overall Klimisch score (Schneider et al., 2009 ). Klimisch et al. (1997) and ToxRTool (European Commission, Undated) each outline scoring frameworks for reporting requirements in completed studies in order to assign a reliability classification ("reliable without restriction," "reliable with restrictions," "not reliable," or "not assignable"). Both systems outline reporting requirements (see Table 4 ) necessary to achieve a "reliable" classification as well as several additional considerations weighted to assign reliability restrictions; however, the criteria differ between the two systems. As noted previously, by design, the ToxRTool guidelines are more explicit than the Klimisch et al. (1997) guidelines on variables that should be considered to achieve a "reliable" classification in each category. For example, the ToxRTool provides more explicit guidance on how to differentiate between Category 2, "reliable with restrictions," and Category 3, "not reliable," which, using Klimisch alone, may be difficult to distinguish between (Schneider et al., 2009) .
The ARRIVE guidelines (Kilkenny et al., 2010) , based off of the Consolidated Standards of Reporting Trials (CONSORT) checklist for randomized clinical trials, provide an outline of "good reporting requirements" for authors to consider during the writing stage of their studies. Rather than providing a scoring framework with which a paper can be rated, as in Klimisch et al. (1997) and ToxRTool (European Commission, Undated), ARRIVE (Kilkenny et al., 2010) provides guidelines intended to improve reporting quality but does not address overall study quality.
As is the case with the epidemiological studies, IRIS also provides "15 questions" to address the risk of bias in animal studies (US EPA, 2014a). The rating system ("þþ," "þ," "À," or "À À") mirrors that used for the epidemiological studies to determine the likelihood of bias for each criterion ("definitely low," "probably low," "probably high," or "definitely high" risk of bias); however, the questions vary slightly to account for the differences inherent to the study type. The IRIS approach bases the overall quality tier (low or high risk of bias) for each study on how many of the 15 questions were rated as a "À À" or a "À", as described in Tables 1e10 and 1e11 of the Agency's Draft Development Materials for Arsenic (US EPA, 2014a).
Unlike the aforementioned systems, OECD GD 34 (OECD, 2005) is not a quality criteria system for authoring or assessing completed studies, but rather provides guidance for the development and validation of new and updated study methods for hazard assessment. In addition to guidelines for methodological considerations, such as species, route of administration, and substance preparation, OECD provides requirements for international validation, including reproducibility and precision of results across laboratories, relevance of the test to the outcome of concern, and uniform reporting practices (OECD, 2005) .
As with the human studies, the IRIS and OHAT rating systems are very similar, and both include a set of 15 questions. The OHAT guidelines, however, again provide more guidance on what constitutes meeting the requirements for each respective score (NTP, 2015b) . Further, the risk of bias guidance document (NTP, 2015b) provides examples of acceptable methods and caveats for some requirements. For example, for randomization, the guidance notes that allocation without a clearly random component may be acceptable for a "probably low risk of bias" rating, if the methods would not "appreciably bias results" (NTP, 2015b) . This determination, the guidance states, may require consultation with a statistician. An example table for use in documenting the characteristics/results and the study quality of animal studies is provided in Table 4 of "Step 4: Assess Quality of Individual Studies" of the perfluorinated compounds assessment (NTP, 2013c) and Appendix 4 of the 2015 OHAT handbook (NTP, 2015a).
As with the IRIS and OHAT evaluation systems, the Navigation Guide system (Koustas et al., 2013 Woodruff and Sutton, 2014) provides a system to determine whether there is "low risk of bias," "probably low risk of bias," or "high risk of bias," (or "not applicable," when appropriate) for a series of risk-of-bias criteria. The Navigation Guide includes many of the same reporting requirements of the other animal study systems. Unlike IRIS and OHAT, however, there are fewer criteria to score risk of bias. The Navigation Guide for animal studies includes a set of seven questions addressing the issues of sequence generation, allocation concealment, blinding of outcome assessment (personnel and outcome assessors), incomplete outcome data, selective outcome reporting, and financial conflict of interest. As noted in the previous section on human studies, this last criterion distinguishes the Navigation Guide. It is the only system that has a scoring system that penalizes publications that are not funded by academic grants, the government, or non-profit organizations.
All of the study guidelines for animal studies consistently note the importance of reporting the test method, animal characteristics, (e.g., species, age, and sex), and the characteristics of the test substance (e.g., purity, composition, and preparation). The use of an established OECD guideline or GLPs are optional but are noted in most of the guidelines. Further, reporting the methodology for the determination of dose groups, route of administration, and housing and husbandry conditions were key to obtaining a "reliable" score in all of the scoring guidelines. The ARRIVE (Kilkenny et al., 2010) , OECD GD 34 (OECD, 2005) , IRIS (US EPA, 2013, 2014a), Navigation Guide (Koustas et al., 2013 Woodruff and Sutton, 2014) and OHAT (NTP, 2013a-c) systems all stress the importance of reporting blinding and subject randomization methods employed by the study, noting that randomization methodology should minimize differences in subject characteristics (such as age and body weight) among groups. All of the guidelines require reporting the outcome assessment methodology and results. However, only the OECD, IRIS, Navigation Guide, and OHAT systems state that all results, statistically significant or not, should be reported.
2 Only two systems (ARRIVE and OECD) require the reporting of study limitations and study interpretation and implications.
In vitro studies are addressed in the ARRIVE (Kilkenny et al., 2010) , Klimisch et al. (1997) , OECD GD 34 (OECD, 2005) , and ToxRTool guidelines (European Commission, Undated), with criteria similar to those for the animal studies. However, only the OECD, IRIS, Navigation Guide, and OHAT systems state that all results, statistically significant or not, should be reported. Only two systems (ARRIVE and OECD) require the reporting of study limitations and study interpretation and implications.
Guidance systems for systematic reviews and evidence integration
In addition to the individual study criteria systems, there are several systems targeted at systematic reviews and evidence integration. In other words, these systems provide guidance on how to review the results of numerous studies at one time and make conclusions based on the strength of the overall body of evidence. We reviewed the US EPA IRIS (US EPA, 2013 , 2014a , NTP OHAT (NTP, 2013a-c), Navigation Guide (Koustas et al., 2013 Woodruff and Sutton, 2014) , and AMSTAR (Shea et al., 2007) criteria systems. Although the IRIS and OHAT systems contain many of the same considerations e the requirement that an ex ante design/protocol for the review should be established; details on the search strategy must be provided; and the body of evidence must be assessed with regards to temporality, magnitude of effect, relevance of endpoints, and other Bradford Hill criteria e there remain potentially important differences between the two systems. For example, OHAT explicitly states that the objective of the systematic review must be stated, whereas this requirement is not stated in IRIS. OHAT also explicitly states that the potential for publication bias must be explored, but this issue is not brought up in the IRIS guidelines. Both IRIS and OHAT lay out fairly specific requirements for data reporting in systematic reviews; they state that study characteristics, results, and study quality should each be provided in tabular format.
The third systematic review system, the Navigation Guide system (Koustas et al., 2013 Woodruff and Sutton, 2014) is almost identical to the OHAT system. The only difference is that OHAT specifically states that the literature identification process should be iterative, a stipulation that is not present in the Navigation Guide. The Navigation Guide provides guidelines on assessing whether the methods to combine findings across studies (i.e., in a meta-analysis) are appropriate, including tests for the heterogeneity of data. The OHAT guidance provides a short section about considering and conducting a meta-analysis, stating that their approach is very similar to the Navigation Guide system (NTP, 2015a) .
The final systematic review criteria system, AMSTAR (Shea et al., 2007) , addresses very similar issues to IRIS and OHAT but tends to be less explicit in certain areas e specifically, assessment of individual study quality and overall confidence in the body of evidence. Unlike IRIS and OHAT, the AMSTAR criteria are not continuous measures and consist of 11 questions, all of which can be answered "yes," "no," "can't answer," or "not applicable." Only two questions address study quality: the first requires only that methods of quality assessment are recorded, and the second requires an assessment of whether the criteria were "appropriate." The only description provided to denote what constitutes an "appropriate" quality criteria is, "The results of the methodological rigor and 2 Note that Good Laboratory Practice (GLP) guidelines require reporting all results, and, as such, the Klimisch system would also require this for an assignment of Category 1. However, as discussed previously, the Klimisch system publication does not explicitly discuss all of the requirements of GLP, and, as such, when used alone (without referencing GLP), it does not explicitly require reporting all results. scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations" (Shea et al., 2007) . Finally, AMSTAR provides no questions regarding the overall confidence in the available body of evidence.
Conclusions

Similarities among criteria systems
Overall, the available study quality reporting and rating systems differ slightly to substantially from one another in terms of their intended purpose and the level of detail with which the reader is guided when making decisions for each of the quality criteria. All systems, however, including human, animal, and in vitro (when applicable) share common themes. These important themes include: adequate reporting of specific details of study conditions and design/protocol; selection and randomization (when appropriate) of study groups; outcome assessment methods and applicability; avoidance of selective reporting; and consideration of potential confounders or bias.
Implications of the data quality criteria systems
There are broad similarities among the data quality criteria systems, in that they all seek to note and document whether any aspect of a study's design or execution might lead to outcomes that may be affected by factors other than the one nominally being examined for its ability to cause the outcomes of concern. That is, the question for individual studies is primarily one of internal validity e the lack of ambiguity about what the study itself can be said to have demonstrated, accomplished through controlling all potential influences aside from the one the study intends to test. Good experimental design aims to eliminate the possible role of such extraneous factors, and the criteria for most data quality evaluation systems require documentation of the steps that a study has taken to eliminate the ones that can be anticipated and addressed.
The ultimate test of the success of experimental design is repeatability; if all extraneous factors have been controlled, then a true effect should appear consistently (within the limits of statistical variability to be expected from the sample sizes used). Only the OECD guidelines, however, explicitly refer to repeatability (OECD, 2005) , and OECD standard protocols are notable for their emphasis on documenting repeatability across practitioners. The advantage of such rigid and tested protocols is their documentation of reliability, but their potential disadvantage e at least for some questions e is that they may not be aimed at new or intermediate endpoints, particulars of underlying biology, or possible roles of novel causation pathways or patterns of dose-dependence.
In particular, emerging technologies, such as high-throughput screening, exemplify the challenges of evaluating study quality with strict criteria systems. For example, although the NTP/US EPA/ National Institutes of Health (NIH) joint Tox21 database (NTP, 2013d) and US EPA's Toxcast program (US EPA, 2014b), which each aim to screen numerous chemical compounds for potential toxicity through the use of in vitro assays, perform some quality control to ensure proper handling and verification of the identity, concentration, purity, and stability of chemical samples being tested, there are no explicit quality criteria built into the processes that evaluate other quality aspects of these assays. Owing to the novelty of these methods, standardizing a set of quality criteria specific to high-throughput assays may pose some challenges, but it is an essential component of applying these data to risk assessment decision making. Emerging techniques and other laboratoryspecific research that have not been fully validated and verified by accepted criteria have similarities to Laboratory Developed Tests (LDTs) as defined by US FDA for use in clinical diagnostics. US FDA is currently working to develop quality management systems for LDTs, which may be useful to adapt for other novel technologies.
Therefore, there will always be studies that do not fully follow a pre-existing, well-standardized, and tested protocol, because they seek to investigate possible causes, endpoints, or susceptibilities in further species and strains beyond those existing in established protocols. The evaluation criteria thus aim to document whether anticipatable extraneous influences have been controlled for, and the list of criteria focuses on measures to control those aspects of design and conduct that, in our understanding and experience, can affect outcomes. For one-off experiments, there is no empirical validation that the controls imposed do, in fact, lead to repeatable findings, and so the sufficiency of quality measures hinges on whether the evaluation criteria indeed capture all of the aspects of the study design and conduct that could have influence. The more novel and unexplored the phenomenon being tested, however, the more it is possible that the standard evaluation criteria do not account for some possible influence. In some cases, some forethought may identify case-specific factors, beyond those in the standard quality evaluation criteria, that should be addressed, and quality evaluation systems should try to evaluate whether this has been adequately done.
The extraneous influences that one aims to control through the design and conduct of a study can broadly be categorized as either sources of random error (increasing variance and, hence, statistical fluctuation in outcomes from one instance to another) and sources of potential systematic error or bias. The evaluation systems we reviewed do not make this distinction strongly, but the intent of some criteria to examine a source of random or systematic error is often clear, though implicit. For example, using vehicle controls aims at reducing systematic error, and randomizing animals among dose groups aims at reducing random error.
For studies of high quality, in which the criteria for good conduct and design are mostly met, the various systems tend to agree in their evaluations. The criteria systems diverge more when it comes to dealing with studies that have a less-than-ideal design or conduct. Some study quality systems simply document the lack of complete fulfillment of one or more of their criteria. Others try to rate the degree of shortcoming on individual criteria with scoring systems. Although we have not explored it here, such scoring schemes raise the question of how the less-than-ideal aspects of a study should be aggregated across specific criteria to provide a characterization of the "overall" quality of any one study. This is distinct from the method that some systems have to arrive at summary quality scores for the body of evidence, although both applications share the question of how the assessments of individual dimensions should add up to a useful and meaningful summary measure. It is not immediately clear if or how a strength in one dimension should be taken to compensate for a shortcoming in another distinct aspect, how an overall score is to be interpreted in terms of relative reliability of study results, or how alternative scoring schemes should be compared to determine reliability and effectiveness. These are issues that deserve further discussion.
Some criteria can be fully met and, therefore, cannot be improved upon, but others (such as sample size or number of dose groups) can always be expanded to a yet-better level, yielding more statistical power, lower variance, or more detailed information about patterns of dose dependency. The criteria for such factors usually address whether these continuously improvable factors are set at an "adequate" level, but the question of adequacy is, in part, convention and, in part, a function of the ultimate application of the data.
In the end, the above questions affect how one thinks about bringing the evaluation of study quality to bear on larger risk assessment questions. No study is absolutely ideal, if only because it could have been conducted with larger sample sizes, more dose levels, or with a broader range of conditions being investigated. Some studies have shortcomings that, to a greater or lesser extent, compromise the dependability of their nominal attribution of outcomes to the tested variable. This is not to say that a study with "greater" quality is necessarily correct or that one with "lesser" quality is wrong. To conclude that a study's shortcomings actually (rather than potentially) compromised its outcome is itself a scientific conclusion that is hard to determine based on a single instance. If studies disagree in outcome, one must decide whether extraneous factors did indeed affect certain outcomes and which outcomes are the ones actually (not just potentially) more affected or less affected. For non-standard experiments, it must also be entertained that the disagreements stem not from the aspects measured in the quality criteria of the rating systems, but rather from some poorly understood contingency of outcomes on a factor that is not captured in the rating systems or, perhaps, is not even recognized by current science.
It must also be remembered that study-specific ratings are about internal validity, and rating criteria recognize and reward study design that narrows the potential influential factors down such that only the tested variable can plausibly influence the outcome. That is, study outcomes are particular instances that are intentionally constrained to a particular setting. Using the data from such a study to make inferences about other matters (such as human hazard potential, for instance) consists of generalizing from these particular instances to other settings, and the applicability to and informativeness of data from a study e no matter how high in quality e to such other settings is a separate evaluation.
To summarize, although study quality evaluation systems vary in the specifics of good study design, conduct, and reporting that are examined, there are several elements that are nearly universally named as essential to recognizing study results as robust and reliable. For human studies, especially for observational epidemiologic studies, these include aspects of care in identifying and choosing study populations, investigating and adequately addressing potential confounding factors, and avoiding selectively reporting results. For animal studies, widely named factors include careful and documented control of animal provenance, environmental conditions, food, and water e all with a particular focus on aspects that might introduce variations in outcomes that are not attributable to the test agent. Also emphasized are the use of appropriate control groups, the randomization of animals among treatments, dependability and documentation of procedures for exposure and for the evaluation of endpoints, and thorough reporting of the outcomes examined. Blinding endpoint evaluators to the dosing status of individual animals is often valued as well. It is recommended that these widely recognized aspects of the evaluation of study quality be incorporated into any further development of evaluation systems.
In the particular case of standardized protocols, there are recognized advantages that the repeatability and reliability of the protocol have been empirically established. Repeatability of execution among laboratories, and of the consistency across cases of responses among control animals, have been documented. Because the things that are standardized in standard protocols are largely the same experimental design and conduct elements that are recognized as key to quality evaluation, documented adherence to protocols is itself a valuable index of study reliability that is readily recognized in a consistent and repeatable way by different practitioners. This said, there is an important role in toxicity evaluation for the broader set of studies that do not adhere to preexisting protocols for various reasons, including the investigation of novel endpoints, other species, or aspects of underlying modes of action and the roles of early and intermediate responses in understanding apical toxicity. Study quality evaluation systems can be valuable for guiding examinations of how (and how well) such studies address concerns about potential impacts on rigor and reliability that are addressed in more codified form in protocol studies.
Note that systems vary in the way they distinguish (or fail to distinguish) shortcomings on actual conduct from mere failure to sufficiently document that the appropriate measures were actually taken. One hopes that, knowing that studies will be judged more useful and of higher quality when fully documented, the level of expected documentation of study design and conduct in scientific publications will increase.
Finally, it should again be emphasized that study quality evaluation bears on the reliability and robustness of the individual study results e whether the outcomes can unambiguously be taken as evidence of the effect of the agent in question in the particular test system. While recognizing that test systems are chosen to be informative about the further question of toxicity potential in human target populations, it should be recognized that study quality is but one aspect e albeit a critically important one e in bringing to bear and integrating the evidence that the studies provide during the process of coming to ultimate judgments about the risk potential of the agent in question in the population for which risks are being assessed.
